A Phase I Study of Gemtuzumab Ozogamicin in Combination With a Myeloablative Conditioning (MAC) Regimen and alloSCT in Children With High-Risk CD33+ AML: A New Targeted Immunochemotherapy Conditioning Regimen (GO-BU/CY)

Autor:	D. George, Prakash Satwani, Mitchell S. Cairo, J. Le Gall, F. Dela Cruz, C. van de Ven, Erin Morris, Zhezhen Jin, Joseph Schwartz, L.A. Baxter-Lowe, James Garvin, Monica Bhatia
Jazyk:	angličtina
Předmět:	Oncology Transplantation medicine.medical_specialty business.industry Gemtuzumab ozogamicin Myeloablative conditioning CD33 Hematology Phase i study Conditioning regimen MAC Regimen Internal medicine medicine business medicine.drug
Zdroj:	Biology of Blood and Marrow Transplantation. (2):S247
ISSN:	1083-8791
DOI:	10.1016/j.bbmt.2010.12.283
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2e34e3708dd3905c05876e86b2ce05d Zobrazit plný text záznamu